Daré Bioscience reported financial results for the quarter ended June 30, 2026. The company generated total revenue of $0.2 million, driven by research and development services from Gates Foundation agreements, compared to negative revenue in the prior year period. Operating expenses were approximately $2.8 million, resulting in a net loss of $2.98 million. As of June 30, 2026, Daré held approximately $12.6 million in cash and cash equivalents with a working capital deficit of $0.2 million. Commercially, the company launched Flora Sync LF5 as its first direct-to-consumer product and is preparing for prescription dispensing of DARE to PLAY Sildenafil Cream in Q3 2026. The pipeline advanced with positive interim Phase 3 results for Ovaprene and initiation of a Phase 2 study for DARE-HPV, supported by $2.0 million in total NIH funding. Daré Bioscience is a biotech company focused on developing women's health products.
